Global Cancer Monoclonal Antibodies Market to Grow at 3.6% During 2024-2032, Propelled by Demand for Efficient Treatments

June 11, 2020 | Healthcare

According to the latest report by IMARC Group, titled "Cancer Monoclonal Antibodies Market Report by Antibody Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, and Others), Medication Type (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), and Others), Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, and Others), End-User (Hospitals and Clinics, Pharmacies, Research Laboratories, and Others), and Region 2024-2032," the global cancer monoclonal antibodies market reached a value of US$ 46.6 Billion in 2023. Cancer monoclonal antibodies refer to laboratory-produced molecules that are designed to treat cancer. These proteins are engineered to mimic the role of antibodies that are naturally produced by the human body to aid the immune system in fighting cancer cells. They further bind to the antigens that are present on the surface of cancer cells, trigger the destruction of cell membranes and block cell growth by obstructing the connection with growth-promoting proteins. As a result, numerous monoclonal antibodies, including murine, chimeric and humanized antibodies, are widely used in the treatment of liver, blood and breast cancer.

Global Cancer Monoclonal Antibodies Market Trends:

The market is primarily driven by the rising prevalence of cancer on the global level. This has increased the requirement for efficient cancer treatments, owing to which monoclonal antibody therapy is gaining prominence in the healthcare sector. Its clinical usage is widely associated with improved outcomes as compared to other forms of cancer therapies. Unlike conventional treatments, such as radiotherapy and chemotherapy, monoclonal antibodies target the cancer cells while leaving the healthy cells unaffected, which minimizes the side effects. The advent of next-generation sequencing (NGS) and target gene selection is acting as another major growth-inducing factor. These technologies have led to the development of cost-effective monoclonal antibodies, which are gaining widespread preference among healthcare professionals. Extensive research and development (R&D) activities in genomics, coupled with the rising healthcare expenditure and investments by government and private entities, are expected to provide an impetus to the market growth. On account of the aforementioned factors, the market is projected to grow at a CAGR of 3.6% during 2024-2032.

Market Summary:

On the basis of the antibody type, the market has been divided into murine antibodies, chimeric antibodies, humanized antibodies and others.
Based on the medication type, the market has been classified into Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix) and others.
On the basis of the application, the market has been categorized into breast, blood, liver, brain, colorectal and other kinds of cancers.
Based on the end users, the market has been segmented into hospitals and clinics, pharmacies, research laboratories and others.
On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
The competitive landscape of the market has been examined in the report with the detailed profiles of the key players. Some of these players include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Segment Coverage	Antibody Type, Medication Type, Application, End-User, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Brazil, Mexico
Companies Covered	AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800 |
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Cancer Monoclonal Antibodies Market to Grow at 3.6% During 2024-2032, Propelled by Demand for Efficient Treatments

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.